Despite generally positive earnings and a cost-savings plan that will reduce the company’s head count by 1,000, shares of Biogen have traded down sharply.
With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu
By Michael Erman NEW YORK (Reuters) - With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting f.